O Rourke DM - Search Results

1

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.

Struve N, Binder ZA, Stead LF, Brend T, Bagley SJ, Faulkner C, Ott L, Müller-Goebel J, Weik AS, Hoffer K, Krug L, Rieckmann T, Bußmann L, Henze M, Morrissette JJD, Kurian KM, Schüller U, Petersen C, Rothkamm K, O Rourke DM, Short SC, Kriegs M. Struve N, et al. Among authors: o rourke dm. Oncogene. 2020 Apr;39(15):3041-3055. doi: 10.1038/s41388-020-1208-5. Epub 2020 Feb 17. Oncogene. 2020. PMID: 32066879 Free PMC article.

2

Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.

Qian X, O'Rourke DM, Zhao H, Greene MI. Qian X, et al. Among authors: o rourke dm. Oncogene. 1996 Nov 21;13(10):2149-57. Oncogene. 1996. PMID: 8950982

3

Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells.

Zhang HT, Zhang X, Zhao HZ, Kajino Y, Weber BL, Davis JG, Wang Q, O'Rourke DM, Zhang HB, Kajino K, Greene MI. Zhang HT, et al. Among authors: o rourke dm. Oncogene. 1997 Jun 19;14(24):2863-9. doi: 10.1038/sj.onc.1201140. Oncogene. 1997. PMID: 9205094

4

Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.

O'Rourke DM, Nute EJ, Davis JG, Wu C, Lee A, Murali R, Zhang HT, Qian X, Kao CC, Greene MI. O'Rourke DM, et al. Oncogene. 1998 Mar 5;16(9):1197-207. doi: 10.1038/sj.onc.1201635. Oncogene. 1998. PMID: 9528862

5

Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.

Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X. Zhang HT, et al. Among authors: o rourke dm. Oncogene. 1998 Jun 4;16(22):2835-42. doi: 10.1038/sj.onc.1201820. Oncogene. 1998. PMID: 9671404

6

Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).

Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM. Wu CJ, et al. Among authors: o rourke dm. Oncogene. 2000 Aug 17;19(35):3999-4010. doi: 10.1038/sj.onc.1203748. Oncogene. 2000. PMID: 10962556

7

The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.

Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI. Wu CJ, et al. Among authors: o rourke dm. Oncogene. 2001 Sep 20;20(42):6018-25. doi: 10.1038/sj.onc.1204699. Oncogene. 2001. PMID: 11593409

8

SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.

Zhan Y, O'Rourke DM. Zhan Y, et al. Among authors: o rourke dm. Cancer Res. 2004 Nov 15;64(22):8292-8. doi: 10.1158/0008-5472.CAN-03-3143. Cancer Res. 2004. PMID: 15548697

9

The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Zhan Y, Counelis GJ, O'Rourke DM. Zhan Y, et al. Among authors: o rourke dm. Exp Cell Res. 2009 Aug 15;315(14):2343-57. doi: 10.1016/j.yexcr.2009.05.001. Epub 2009 May 8. Exp Cell Res. 2009. PMID: 19427850 Free PMC article.

10

SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration.

Kapoor GS, O'Rourke DM. Kapoor GS, et al. Among authors: o rourke dm. Oncogene. 2010 Jul 22;29(29):4130-44. doi: 10.1038/onc.2010.164. Epub 2010 May 17. Oncogene. 2010. PMID: 20473329

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

190 results

Search Page

Filters